NYU Langone Health

Study Designs Completed for NIH Consortium Study of Long-term COVID-19

Wednesday, September 15, 2021 - 4:41pm

As the CSC for the NIH grant, NYU Langone is charged with integrating the research activities of clinical sites around the country.

Key Points: 
  • As the CSC for the NIH grant, NYU Langone is charged with integrating the research activities of clinical sites around the country.
  • As of August 25, more than 39 million Americans had been infected with COVID-19, resulting in 648,000 deaths.
  • The study will also seek to enroll participants without SARS-CoV-2 infection to serve as a comparison group.
  • An important aspect of the RECOVER Initiative is the development of the pediatric main protocol for study of Long COVID in children.

Many Mothers May Have Delayed or Abandoned Plans for Additional Children Because of COVID-19 Pandemic

Wednesday, September 15, 2021 - 4:00pm

"This is yet another example of the potential long-lasting consequences of the pandemic beyond the more obvious health and economic effects."

Key Points: 
  • "This is yet another example of the potential long-lasting consequences of the pandemic beyond the more obvious health and economic effects."
  • Early evidence has already identified a birthrate decline in the United States during the coronavirus pandemic.
  • In addition, those with higher stress levels and greater financial insecurity were especially likely to postpone or end their plans for an additional child.
  • Funding for the study was provided by National Institutes of Health grants UH3 0D023305 and K99 ES030403.

Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress

Monday, September 13, 2021 - 12:01pm

DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress, taking place Sept. 16-21, 2021.

Key Points: 
  • DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress, taking place Sept. 16-21, 2021.
  • "We're pleased to share updates from the nemvaleukin development program with the scientific and medical community at ESMO.
  • Details of the presentations are as follows:
    Presentation Date: The poster presentation will be available on demand to attendees beginning Sept. 16, 2021.
  • The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.

Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress

Monday, September 13, 2021 - 12:01pm

DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress, taking place Sept. 16-21, 2021.

Key Points: 
  • DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress, taking place Sept. 16-21, 2021.
  • "We're pleased to share updates from the nemvaleukin development program with the scientific and medical community at ESMO.
  • Details of the presentations are as follows:
    Presentation Date: The poster presentation will be available on demand to attendees beginning Sept. 16, 2021.
  • The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.

Canines 'Out-Sniff' Technology in Detecting Prostate Cancer in Men

Friday, September 10, 2021 - 2:00pm

The study consisted of 126 participants who were placed in one of two groups: a prostate cancer group (n=66) and a control group (n=60).

Key Points: 
  • The study consisted of 126 participants who were placed in one of two groups: a prostate cancer group (n=66) and a control group (n=60).
  • The prostate cancer group was exclusive to men with prostate cancer, ranging from early stage to late state disease.
  • The control group included both men and women, some of which had cancer, some who did not, but no one within the control group had prostate cancer.
  • In a world full of technology, it appears dogs are better able to naturally screen for prostate cancer than our most advanced technology.

First Real-World Data on the Utility of Device-derived Daily Activity, a Novel Digital Biomarker, to Predict Ventricular Arrhythmias

Thursday, September 9, 2021 - 2:30pm

While prior studies have shown an association between activity and outcomes, no studies had examined the temporal relationship between device-derived daily activity, a novel digital biomarker, and ventricular tachyarrhythmias (VT).

Key Points: 
  • While prior studies have shown an association between activity and outcomes, no studies had examined the temporal relationship between device-derived daily activity, a novel digital biomarker, and ventricular tachyarrhythmias (VT).
  • The authors found temporal decline in device-derived activity following ventricular arrhythmias treated with a shock, but not in patients treated with anti-tachycardia pacing (ATP).
  • Monitoring device-derived activity post-VT events with a shock could provide relevant clinical information and potentially warrant intensified treatment.
  • "The CERTITUDE registry represents a robust post-market database consisting of over55,000 active patients monitored by the BIOTRONIK Home Monitoring system.

Off-Target Immune System Response Could Predict COVID-19 Severity

Thursday, September 9, 2021 - 2:00pm

Patients with these elevated levels of autoimmune antibodies were five to seven times more likely to develop severe disease than those whose antibodies levels were stable.

Key Points: 
  • Patients with these elevated levels of autoimmune antibodies were five to seven times more likely to develop severe disease than those whose antibodies levels were stable.
  • Publishing in the journal Life Science Alliance online Sept. 9, the team's latest work is based on the nature of antibodies, they explain, immune proteins that target invading bacteria and viruses.
  • Levels of anti-DNA and anti- phosphatidylserine antibodies were then strongly linked to severity of illness.
  • "Our study adds evidence to the underlying premise of the disease that the misguided immune system's response is doing more damage than the actual viral infection itself."

Steven B. Orr, MD is recognized by Continental Who's Who

Friday, September 3, 2021 - 8:52pm

NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Steven B. Orr, MD, is being recognized by Continental Who's Who as a Trusted Orthopedist for his superb work at RYC Orthopedics.

Key Points: 
  • NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Steven B. Orr, MD, is being recognized by Continental Who's Who as a Trusted Orthopedist for his superb work at RYC Orthopedics.
  • He specialized in hand and upper extremity surgeries, including conditions of the hand, wrist, forearm, and elbow.
  • From a formative age, Dr. Orr grew interested in hand surgery due to his love of playing the piano.
  • He also garnered inspiration from his father, an accomplished ENT, who gave his son a collection of scrub caps to use for surgery.

Joseph D. Zuckerman, MD, FAAOS, Receives American Academy of Orthopaedic Surgeons' Highest Leadership Honor

Thursday, September 2, 2021 - 5:30pm

SAN DIEGO, Sept. 2, 2021 /PRNewswire/ --The American Academy of Orthopaedic Surgeons (AAOS) presented its 2021 William W. Tipton Jr., MD, Leadership Award to Joseph D. Zuckerman, MD, FAAOS.

Key Points: 
  • SAN DIEGO, Sept. 2, 2021 /PRNewswire/ --The American Academy of Orthopaedic Surgeons (AAOS) presented its 2021 William W. Tipton Jr., MD, Leadership Award to Joseph D. Zuckerman, MD, FAAOS.
  • The Tipton Leadership Award recognizes AAOS members who have demonstrated outstanding leadership qualities that have benefitted the orthopaedic community, patients, and/or the American public.
  • Dr. Zuckerman has served as an ambassador of American orthopaedic surgery in the United States and beyond through the American Orthopaedic Association's (AOA) North American Traveling Fellowship and American-British-Canadian Traveling Fellowship.
  • With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world's largest medical association of musculoskeletal specialists.

Decades After Toxic Exposure, 9/11 First Responders May Still Lower Their Risk of Lung Injury

Thursday, September 2, 2021 - 2:00pm

Experts have long feared that this exposure would later lead to lung disease in first responders.

Key Points: 
  • Experts have long feared that this exposure would later lead to lung disease in first responders.
  • Adjusting at least one of these factors, the study investigators found, can greatly lower the risk of firefighters' developing lung disease within five years, even 20 years after toxic exposures at Ground Zero.
  • For example, for a male firefighter of average height, a 7-pound weight loss could decrease his risk for lung injury by 20 percent.
  • In addition, the investigation is the first to date to quantify how adjusting one or more of these risk factors changes lung disease risk.